Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Status:
Withdrawn
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of Phase 1b of the study is to determine the maximum tolerated dose,
pharmacokinetics (PK) and pharmacodynamics (PDn) and assess the safety, tolerability and
activity of oprozomib in combination with sorafenib in subjects with advanced hepatocellular
carcinoma (HCC).
The purpose of Phase 2 of the study is to evaluate the efficacy of oprozomib in combination
with sorafenib versus sorafenib alone and to compare the key outcome measures for subjects
with advanced HCC.